company background image
BXN

BioxyneASX:BXN Stock Report

Market Cap

AU$14.7m

7D

4.5%

1Y

91.7%

Updated

15 Oct, 2021

Data

Company Financials
BXN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BXN Overview

Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes dietary supplement and beauty products.

Price History & Performance

Summary of all time highs, changes and price drops for Bioxyne
Historical stock prices
Current Share PriceAU$0.023
52 Week HighAU$0.01
52 Week LowAU$0.035
Beta1.01
1 Month Change-17.86%
3 Month Change-23.33%
1 Year Change91.67%
3 Year Change-39.47%
5 Year Change15.01%
Change since IPO-87.90%

Recent News & Updates

Shareholder Returns

BXNAU Personal ProductsAU Market
7D4.5%1.2%0.1%
1Y91.7%15.6%19.3%

Return vs Industry: BXN exceeded the Australian Personal Products industry which returned 15.6% over the past year.

Return vs Market: BXN exceeded the Australian Market which returned 19.3% over the past year.

Price Volatility

Is BXN's price volatile compared to industry and market?
BXN volatility
BXN Beta1.01
Industry Beta0.70
Market Beta1

Stable Share Price: BXN is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BXN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1998n/aNam Chuahttps://www.bioxyne.com

Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes dietary supplement and beauty products. The company operates in two segments, Wholesale Sales and Direct Sales. It engages in developing a range of functional foods and beauty products.

Bioxyne Fundamentals Summary

How do Bioxyne's earnings and revenue compare to its market cap?
BXN fundamental statistics
Market CapAU$14.72m
Earnings (TTM)-AU$495.72k
Revenue (TTM)AU$2.20m

6.7x

P/S Ratio

-29.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BXN income statement (TTM)
RevenueAU$2.20m
Cost of RevenueAU$1.03m
Gross ProfitAU$1.18m
ExpensesAU$1.67m
Earnings-AU$495.72k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.00077
Gross Margin53.31%
Net Profit Margin-22.49%
Debt/Equity Ratio0.0%

How did BXN perform over the long term?

See historical performance and comparison

Valuation

Is Bioxyne undervalued compared to its fair value and its price relative to the market?

7.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: BXN (A$0.02) is trading above our estimate of fair value (A$0)

Significantly Below Fair Value: BXN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BXN is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.

PE vs Market: BXN is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BXN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BXN is overvalued based on its PB Ratio (7.8x) compared to the AU Personal Products industry average (3x).


Future Growth

How is Bioxyne forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.0%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioxyne has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Bioxyne performed over the past 5 years?

-8.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BXN is currently unprofitable.

Growing Profit Margin: BXN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BXN is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare BXN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BXN is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).


Return on Equity

High ROE: BXN has a negative Return on Equity (-25.63%), as it is currently unprofitable.


Financial Health

How is Bioxyne's financial position?


Financial Position Analysis

Short Term Liabilities: BXN's short term assets (A$2.5M) exceed its short term liabilities (A$744.7K).

Long Term Liabilities: BXN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: BXN is debt free.

Reducing Debt: BXN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BXN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BXN is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 9.4% per year.


Dividend

What is Bioxyne current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BXN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BXN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BXN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.7yrs

Average board tenure


CEO

Nam Chua

4.33yrs

Tenure

AU$144,409

Compensation

Mr. Nam Hoat Chua, BA, has been the Chief Executive Officer and Managing Director of Bioxyne Limited since June 13, 2017. Mr. Chua served as Vice President of Asia Operations of New Image Group Limited for...


CEO Compensation Analysis

Compensation vs Market: Nam's total compensation ($USD107.09K) is below average for companies of similar size in the Australian market ($USD300.24K).

Compensation vs Earnings: Nam's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: BXN's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bioxyne Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Bioxyne Limited
  • Ticker: BXN
  • Exchange: ASX
  • Founded: 1998
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: AU$14.723m
  • Shares outstanding: 640.15m
  • Website: https://www.bioxyne.com

Location

  • Bioxyne Limited
  • 50 Clarence Street
  • Suite 506
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/15 15:49
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.